Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system

References

• Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. Vol. 4, Lyon: IARC Press; 2012.
   Google Scholar
• Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–R56. doi:10.1186/bcr767.
   PubMed Web of Science ®Google Scholar
• Biglia N, Maggiorotto F, Liberale V, Bounous VE, Sgro LG, Pecchio S, D’Alonzo M, Ponzone R. Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol. 2013;39(5):455–14. doi:10.1016/j.ejso.2013.02.007.
   PubMed Web of Science ®Google Scholar
• Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046–1052. doi:10.1038/sj.bjc.6602787.
   PubMed Web of Science ®Google Scholar
• Porter AJ, Evans EB, Foxcroft LM, Simpson PT, Lakhani SR. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol. 2014;58(1):1–10. doi:10.1111/1754-9485.12080.
   PubMed Web of Science ®Google Scholar
• Hadjiminas DJ, Zacharioudakis KE, Tasoulis MK, Hu JC, Lanitis S, Bright-Thomas R, Dimopoulos NG, Hornzee G, Cunningham DA, Cleator SJ, et al. Adequacy of diagnostic tests and surgical management of symptomatic invasive lobular carcinoma of the breast. Ann R Coll Surg Engl. 2015;97(8):578–583. doi:10.1308/rcsann.2015.0034.
   PubMed Web of Science ®Google Scholar
• Farese SA, Aebi S. Infiltrating lobular carcinoma of the breast: systemic treatment. Breast Dis. 2008;30:45–52. doi:10.3233/BD-2009-0281.
   PubMedGoogle Scholar
• Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy. Breast J. 2012;18(6):569–574. doi:10.1111/tbj.2012.18.issue-6.
   PubMed Web of Science ®Google Scholar
• Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007;8(1):55–62. doi:10.1016/S1470-2045(06)71011-7.
   PubMed Web of Science ®Google Scholar
• Truin W, Vugts G, Roumen RM, Maaskant-Braat AJ, Nieuwenhuijzen GA. van der Heiden-van der Loo M. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2016;23:51–57.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–675. doi:10.1146/annurev.cellbio.17.1.615.
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13(20):6064–6069. doi:10.1158/1078-0432.CCR-07-0266.
   PubMed Web of Science ®Google Scholar
• Christgen M, Noskowicz M, Schipper E, Christgen H, Heil C, Krech T, Länger F, Kreipe H, Lehmann U. Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes, Chromosomes Cancer. 2013;52(1):69–80. doi:10.1002/gcc.v52.1.
   PubMed Web of Science ®Google Scholar
• Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506–519. doi:10.1016/j.cell.2015.09.033.
   PubMed Web of Science ®Google Scholar
• Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, et al. Genomic characterization of primary invasive lobular breast cancer. J Clinical Oncol. 2016;34(16):1872–1881. doi:10.1200/JCO.2015.64.0334.
   PubMed Web of Science ®Google Scholar
• Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep. 2016;6:18517. doi:10.1038/srep18517.
   PubMed Web of Science ®Google Scholar
• Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10(5):437–449. doi:10.1016/j.ccr.2006.09.013.
   PubMed Web of Science ®Google Scholar
• Doornebal CW, Klarenbeek S, Braumuller TM, Klijn CN, Ciampricotti M, Hau CS, Hollmann MW, Jonkers J, de Visser KE. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res. 2013;73(1):353–363. doi:10.1158/0008-5472.CAN-11-4208.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Dituri F, Mazzocca A, Giannelli G, Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol. 2011;2011:947858. doi:10.1155/2011/947858.
   PubMedGoogle Scholar
• Xue G, Zippelius A, Wicki A, Mandala M, Tang F, Massi D, Hemmings BA. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. J Natl Cancer Inst. 2015;107:7. doi:10.1093/jnci/djv171.
   Google Scholar
• Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4(4):313–319. doi:10.1038/ni0403-313.
   PubMed Web of Science ®Google Scholar
• Karlsson E, Perez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck A-L, Stål O, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013;15(5):R96. doi:10.1186/bcr3557.
   PubMed Web of Science ®Google Scholar
• Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Cajal SRY. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 2007;13(1):81–89. doi:10.1158/1078-0432.CCR-06-1560.
   PubMed Web of Science ®Google Scholar
• Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70(1):288–298. doi:10.1158/0008-5472.CAN-09-1751.
   PubMed Web of Science ®Google Scholar
• Wei F, Zhang Y, Geng L, Zhang P, Wang G, Liu Y. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci. 2015;16(2):3267–3282. doi:10.3390/ijms16023267.
   PubMed Web of Science ®Google Scholar
• Fujishita T, Kojima Y, Kajino-Sakamoto R, Taketo MM, Aoki M. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. Oncogene. 2017;36:6480–6489.
   PubMed Web of Science ®Google Scholar
• Gardner A, Ruffell B. Dendritic Cells and Cancer Immunity. Trends Immunol. 2016;37(12):855–865. doi:10.1016/j.it.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med. 2012;18(3):344–346. author reply 6. doi:10.1038/nm.2652.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi:10.1126/science.1203543.
   PubMed Web of Science ®Google Scholar
• Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324–337. doi:10.1038/nri2546.
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Di Lorenzo A, Rascio F, Zaza G, Grandaliano G. mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med. 2016;14(1):152. doi:10.1186/s12967-016-0916-7.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960–976. doi:10.1016/j.cell.2017.02.004.
   PubMed Web of Science ®Google Scholar
• Chaoul N, Fayolle C, Desrues B, Oberkampf M, Tang A, Ladant D, Leclerc C. Rapamycin impairs antitumor CD8+ T-cell responses and vaccine-induced tumor eradication. Cancer Res. 2015;75(16):3279–3291. doi:10.1158/0008-5472.CAN-15-0454.
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, et al. The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. Radiat Res. 2014;182(2):219–229. doi:10.1667/RR13511.1.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 2011;71(12):4074–4084. doi:10.1158/0008-5472.CAN-10-3968.
   PubMed Web of Science ®Google Scholar
• Raich-Regue D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology. 2016;5(6):e1146841. doi:10.1080/2162402X.2016.1146841.
   PubMed Web of Science ®Google Scholar
• Raich-Regue D, Rosborough BR, Watson AR, McGeachy MJ, Turnquist HR, Thomson AW. mTORC2 deficiency in myeloid dendritic cells enhances their allogeneic Th1 and Th17 stimulatory ability after TLR4 ligation in vitro and in vivo. J Immunol. 2015;194:4767–4776.
   PubMed Web of Science ®Google Scholar
• Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW. Rapamycin inhibits IL-4–induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101(11):4457–4463. doi:10.1182/blood-2002-11-3370.
   PubMed Web of Science ®Google Scholar
• Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5(2):228–236. doi:10.1046/j.1600-6143.2004.00673.x.
   PubMed Web of Science ®Google Scholar
• Zeng H. mTOR signaling in immune cells and its implications for cancer immunotherapy. Cancer Lett. 2017;408:182–189. doi:10.1016/j.canlet.2017.08.038.
   PubMed Web of Science ®Google Scholar
• Keller HR, Zhang X, Li L, Schaider H, Wells JW. Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget. 2017;8(43):75675–75686. doi:10.18632/oncotarget.v8i43.
   PubMedGoogle Scholar
• Colli LM, Machiela MJ, Zhang H, Myers TA, Jessop L, Delattre O, Yu K, Chanock SJ. Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. 2017;77(13):3666–3671. doi:10.1158/0008-5472.CAN-16-3338.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R. The combination of checkpoint immunotherapy and targeted therapy in cancer. Ann Transl Med. 2017;5(19):388. doi:10.21037/atm.
   PubMed Web of Science ®Google Scholar
• Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol Res. 2016;4(7):611–620. doi:10.1158/2326-6066.CIR-15-0252.
   PubMed Web of Science ®Google Scholar
• Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. J Exp Clin Cancer Res. 2019;38(1):127.
   PubMed Web of Science ®Google Scholar
• Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. doi:10.1038/ncomms11479.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–399. doi:10.1038/nature10933.
   PubMed Web of Science ®Google Scholar
• Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–409. doi:10.1038/nature11154.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400–404. doi:10.1038/nature11017.
   PubMed Web of Science ®Google Scholar
• Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S C, Wan A, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518(7539):422–426. doi:10.1038/nature13952.
   PubMed Web of Science ®Google Scholar
• Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201. doi:10.1371/journal.pmed.1002201.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD. PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2017;45(D1):D183–D9. doi:10.1093/nar/gkw1138.
   PubMed Web of Science ®Google Scholar
• Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010;26(17):2176–2182. doi:10.1093/bioinformatics/btq401.
   PubMed Web of Science ®Google Scholar